Connect with us
nairametrics

Business News

Quick take: Fidelity Bank starts year on a good note as earnings beat estimates

Fidelity Bank Plc kicked off 2019 on an impressive note as Q1 2019 results showed that Gross Earnings grew 11.8% y/y to N48.4bn.

Published

on

CBN / Fidelity Bank Plc,

Fidelity Bank Plc kicked off 2019 on an impressive note as its latest Q1 2019 results showed that Gross Earnings grew 11.8% y/y to N48.4bn (annualised; N193.7bn), coming above our FY 2019 estimate of N190.9bn.

Buoyed by the strong growth of 47.5% y/y in Net Fee and Commission Income and a jump of  230% y/y in the Other Income line, Pre-tax Profit grew strongly 34.0% y/y to N6.7bn (annualised; N26.7bn), which is slightly ahead of our 2019 estimate of N25.9bn. The sturdy growth in the Other Income line was bolstered by net foreign exchange gains of N2.3bn realised in Q1 2019 compared to N146m in Q1 2018.

Interest Income grew 2.6% y/y to N38.7bn. On a q/q basis, Interest Income was up 16.2% q/q. On the other hand, Interest Expense rose 6.5% y/y and 4.7% q/q to N22.9 bn, on the back of growth in Customer Deposits, up 18% y/y and 4% q/q. Notably, Customers Deposits crossed the N1trn mark as it closed at  N1.01trn in Q1 2019 (Q1 2018; N859.4bn)- we view this positively.

Further down the Income Statement, the bank recorded an impressive growth of 47.5% y/y to N5.4bn in Net Fee and Commission Income, on the back of higher account maintenance charges (up 28% y/y), Commission on travellersí cheque and foreign bills (up 40% y/y) and Commission on E-banking activities (up 74% y/y).

We attribute the improvement in these income lines to the bankís retail strategy, which involves the use of technology in delivering exceptional banking services.

GTBank 728 x 90

Although, Impairment Charges grew 47% y/y, Cost of Risk (COR)  remained flat at 0.4% in Q1 2019, which is below our 2019 COR estimate of 0.7%.

Despite the mild decline of 2.5% y/y in Net Interest Income, Operating Income grew 17.3% y/y to N24.4bn in Q1 2019 from N20.8bn in Q1 2018.

Although, Operating Expenses grew 10.4% y/y to N16.7bn, the higher growth in Operating Income (+17.3% y/y) led to a 427bps decline in Cost to Income Ratio ( CIR ex-provisions) to 68.4% in Q1 2019 from 72.7% in Q1 2018, which was slightly below our 2019 estimate of 69.0%.

Deal book 300 x 250
Coronation ads

Overall, Pre-tax Profit grew by 34% y/y to N6.7bn (Q1 2018; N4.9bn) while Profit after tax grew 28% y/y to N5.9bn, albeit the slower growth in PAT was due to the higher effective tax rate of 11% compared to 7.1% in Q1 2018. EPS came in at N0.21 in Q1 2019 compared to No.16 in Q1 2018. Annualised RoAE also improved to 12.0% in Q1 2019 compared to 9.7% in Q1 2018.

We have a target price of N2.79/s for Fidelity with a Buy recommendation. Current price: N1.91/s.


CSL STOCKBROKERS LIMITED CSL Stockbrokers,

Member of the Nigerian Stock Exchange,

Jaiz bank ads

First City Plaza, 44 Marina,

Stanbic IBTC

PO Box 9117,

Lagos State,

NIGERIA.

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Business News

#EndSARS: CACOVID earmarks over N250 billion to rebuild police stations and create jobs

CACOVID has budgeted nothing less than N250 billion to rehabilitate damaged police stations across the country and solve the issue of unemployment.

Published

on

Over N27 billion received, what has CACOVID been up to?

The Coalition Alliance Against COVID (CACOVID) has budgeted nothing less than N250 billion to rehabilitate damaged police stations across the country and solve the issue of unemployment.

This is in response to the post-EndSARS violence which led to the loss of lives and valuable property last October.

This is according to a recent press release by the CBN, and seen by Nairametrics. The latest action is sequel to series of decisions reached at the stakeholders’ engagement under the CACOVID, which is aimed at developing measures that will support the government’s effort in rebuilding confidence in the nation’s economy.

What you should know

• In a bid to further strengthen the security apparatus in the country, CACOVID has committed to providing over N100 billion to procure equipment and gadgets for the Nigerian Police Force over the next 2 years.

GTBank 728 x 90

• It also earmarked the sum of over N150 billion to set up and implement the Youth Development Programme which will be available at selected training centres across the country. The programme is expected to provide vocational and technical education for at least 4 million Nigerian youths over the next 5 years, with beneficiaries getting trained on craftwork, plumbing, masonry, carpentry, and other artisanal related skills for which sufficient demand exist in Nigeria.

(READ MORE: COVID-19 Palliatives: CACOVID donation is 95% complete – PTF)

  • The selected student/beneficiaries will be eligible to access a N25 billion fund domiciled to support the entrepreneurial drive of the beneficiaries
  • For the out-of-school graduates that possess certain Entrepreneurial skills, CACOVID will be working with Bankers Committee to complete the Creative center at National Arts Theater area of Lagos in four select areas namely; ICT and software design/development, Fashion, Music and Movies. This project is expected to cost the Bankers Committee over N40 Billion.

Other key resolutions of the Alliance include;

Coronation ads
  • Banks and financial institutions would be required to extend relief through concessionary loans to affected businesses and firms, so they can rebuild and restock their stores and continue to conduct their business activities
  • CACOVID has committed to fully rehabilitate all 44 damaged and destroyed police stations nationwide in a bid to restore provision of security in affected locations.

Why it matters

The response is a way of complementing the Federal Government’s effort of rebuilding the economy which has been badly affected by the pandemic and violent demonstrations. As a way of forestalling future occurrences, CACOVID highlighted unemployment as a key issue that ought to be addressed, in lieu of that, a Youth Development Fund which is aimed at advancing entrepreneurship in the country, is mooted.

Continue Reading

Coronavirus

Covid-19: African Union in talks with China and Russia over vaccine

The AU and Africa CDC have revealed that they have reached out to both China and Russia over the possibility of vaccine partnerships.

Published

on

Covid-19: African Union in talks with China and Russia over vaccine

The Africa Centres for Disease Control and Prevention and the African Union announced they have been in talks with China and Russia over the possibility of vaccine partnerships to ensure that Africa is not left behind when vaccines become available.

This was disclosed by John Nkengasong, Africa CDC Chief, at the Bloomberg Invest Africa online conference.

READ: Covid-19: Pfizer to file for emergency authorization for its vaccine, reaches safety milestone

Mr. Nkengasong said that Africa would not limit itself to only one vaccine partner and that Africa was willing to work with as many partners as possible to provide a vaccine for its 1.2 billion people.

“We are not limiting ourselves to any particular partner. As a continent of 1.2 billion people, we are willing to work with any partner who adheres to our strategic plan for vaccine development and access in Africa.

“The continent is taking the access and development of vaccine very, very seriously. We really need to see clinical trials being done on the continent, so they address issues like background infections from other diseases.”
He disclosed that the Africa CDC resumed talks last week with China, to discuss partnerships with Chinese Drug Manufacturers and also clinical trials in Africa. He added that Russia has been approached with a similar plan.

He said that the WHO Covax programme only covers 20% of the population, but Africa will need 60% of its population vaccinated to achieve herd immunity.

GTBank 728 x 90

There are multiple avenues being explored now to make sure Africa has the appropriate doses of vaccines and also that we have that in a timely fashion, not in a delayed manner,” Nkengasong said.

He revealed that the AFREXIM Bank agreed to finance vaccine procurement with $5 billion and is waiting to see how much it will receive from World Bank’s $12 billion vaccine procurement fund for developing nations.

READ: COVID-19: G-20 to extend debt relief to developing nations

Coronation ads

What you should know 

Nairametrics reported earlier this month that Pfizer Inc. disclosed that its experimental vaccine, which is jointly developed with BioNTech, was more than 90% effective in preventing COVID-19, based on initial data from a large study in the ongoing phase 3 trials.

(READ MORE: COVID-19: AstraZeneca vaccine could be 90% effective against the virus)

Last week, a pharmaceutical company, Moderna Inc., stated that its COVID-19 vaccine was 94.5% effective in treating coronavirus, after preliminary analysis of a large late-stage clinical trial.

The G-20 nations also announced a pledge to pay for vaccine distribution to developing nations that could not afford it. The leaders also unveiled a debt extension programme to developing nations during the weekend’s G-20 summit.

Jaiz bank ads

The Federal Government of Nigeria also announced through the Ministry of Health, that it would inaugurate an 18-man Covid-19 Vaccine Task Team, in a bid to ensure vaccine security In Nigeria.

Stanbic IBTC

Continue Reading

Coronavirus

Covid-19: EU considers skipping vaccine patents to boost vaccine access

The EU has disclosed plans to increase its access to Covid-19 vaccines by offering financial incentives to vaccine production companies.

Published

on

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns, COVID-19: J&J starts vaccine trials on humans after success on monkeys

The European Union (EU) says its planning emergency measures to increase its access to Covid-19 vaccines including sidestepping patent rights and offering financial incentives to vaccine production companies to move production to Europe.

This was revealed in an EU document on Wednesday and reported by Reuters. The Document says the EU may create an emergency coordination mechanism to be issued at short notice when the EU needs a vaccine license, which is different from fully patent waivers, discussed in the WTO last week.

READ: COVID-19: EU to buy up to 300million doses of BioNTech-Pfizer’s COVID-19 vaccine

The EU says the new move will ensure faster procedures during a pandemic, which will enable generic production in the EU without the consent of patent holders.

The Commission sees the need to ensure that effective systems for issuing compulsory licenses are in place, to be used as a means of last resort and a safety net, when all other efforts to make IP (intellectual property) available have failed,” the EU’s document said.

GTBank 728 x 90

READ: COVID-19 boosts Fidson Healthcare Plc’s Q2 2020 performance

The EU’s actions may be triggered by its inability to access the antiviral drug, remdesivir, during the pandemic, as the United States ordered most of the stock.

READ: U.S dollar drops, Currency traders fear increasing COVID-19 caseloads

Coronation ads

The EU also disclosed that it will begin a consultation process with pharmaceutical companies next year to address issues in its pharmaceutical value chains. They added that measures could be imposed to encourage manufacturers to move pharmaceutical production to Europe from China and India.

“The Commission calls on member states to ensure that the tools they have are as effective as possible; for instance, by putting in place fast-track procedures for issuing compulsory licenses in emergency situations,” the EU said.

READ: COVID-19: Vaccine Alliance says vaccine might cost a maximum of $40 per dose

They added that it is urgent “to assess whether manufacturing capacity for certain critical medicines may be required in the EU.”

“We need to be able to rely on ourselves, not on others,” the Commission’s Vice President, Margaritis Schinas said. He disclosed that the EU is working on more compliance with drug supply need and increased stock levels by 2022.

Jaiz bank ads

What you should know

Stanbic IBTC

This comes as surprise considering the EU rejected a World Trade Organization (WTO) proposal last week to waive the intellectual property rights needed for the manufacturing of Covid-19 vaccines. The waiver would have made the vaccine access cheaper for developing nations.

Continue Reading